Related references
Note: Only part of the references are listed.Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib
Astrid A. M. van der Veldt et al.
ANTI-CANCER DRUGS (2010)
Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients
Toru Mukohara et al.
CANCER SCIENCE (2010)
Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
Christina M. Annunziata et al.
CLINICAL CANCER RESEARCH (2010)
Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma
Chih-Hsun Yang et al.
EXPERT OPINION ON DRUG SAFETY (2010)
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Michael Friedlander et al.
GYNECOLOGIC ONCOLOGY (2010)
Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non-Small-Cell Lung Cancer
Nasser Altorki et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
Thomas E. Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Application of a PDGF-containing novel gel for cutaneous wound healing
R. Judith et al.
LIFE SCIENCES (2010)
Pazopanib
Ronald M. Bukowski et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
Fabio M. Iwamoto et al.
NEURO-ONCOLOGY (2010)
A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium
Sara K. Taylor et al.
ONCOLOGIST (2010)
Lack of Association Between Excretion of Sorafenib in Sweat and Hand-Foot Skin Reaction
Lokesh Jain et al.
PHARMACOTHERAPY (2010)
Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non-Renal Cell Carcinoma: A Meta-analysis
David Chu et al.
CLINICAL GENITOURINARY CANCER (2009)
Sunitinib in solid tumors
Hui K. Gan et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors
Ferry A. L. M. Eskens et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Risk of hand-foot skin reaction with sorafenibo: A systematic review and metes-analysis
David Chu et al.
ACTA ONCOLOGICA (2008)
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
M. E. Lacouture et al.
ANNALS OF ONCOLOGY (2008)
Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
Mario E. Lacouture et al.
ONCOLOGIST (2008)
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib
C. Porta et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2007)
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma
Hideyuki Akaza et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer
Cheryl A. Grandinetti et al.
PHARMACOTHERAPY (2007)
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors
Joachim Drevs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Rakesh Kumar et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
D Strumberg et al.
EUROPEAN JOURNAL OF CANCER (2006)
BAY 43-9006 inhibition of oncogenic RET mutants
F Carlomagno et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert et al.
LANCET ONCOLOGY (2005)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Share Paper
